Skip to main content
. 2013 Dec 19;7(12):e2599. doi: 10.1371/journal.pntd.0002599

Figure 2. The effect of methylprednisolone (MP) treatment on serum levels of IL-17A.

Figure 2

(A) IL-17A levels in serum samples obtained from control (Ctrl, n = 20) and HFMD patients (HFMD, n = 40). (B) IL-17A levels in serum samples obtained from untreated (n = 27) or MP-treated HFMD patients (n = 13). (C) IL-17A levels in serum samples obtained from untreated (n = 7) or MP-treated CNS-complicated HFMD patients (n = 13). Numbers above square brackets indicate P values for the corresponding comparisons.